<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05067309</url>
  </required_header>
  <id_info>
    <org_study_id>Soh-Med-21-09-07</org_study_id>
    <nct_id>NCT05067309</nct_id>
  </id_info>
  <brief_title>Termination of Early Pregnancy in Scarred Uterus With Lletrozole and Misoprostol Compared to Misoprostol Alone</brief_title>
  <official_title>Termination of Early Pregnancy in Scarred Uterus With Letrozole and Misoprostol Compared to Misoprostol Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ahmed Elsayed Aref</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Termination of early pregnancy in scarred uterus with letrozole and misoprostol compared to&#xD;
      Misoprostol alone&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Complete abortion of early pregnancy with letrozole then misoprostol</measure>
    <time_frame>6 months</time_frame>
    <description>Letrozole increase cervical ripening</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Termination of Early Pregnancy in Scarred Uterus</condition>
  <arm_group>
    <arm_group_label>Missed abortion received letrozole then misoprostol</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Missed abortion received misoprostol alone</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole 2.5mg</intervention_name>
    <description>Missed abortion received letrozole then misoprostol</description>
    <arm_group_label>Missed abortion received letrozole then misoprostol</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Termination of early pregnancy in scarred uterus with letrozole and misoprostol compared to&#xD;
        Misoprostol alone&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Minimum age of 18 years for mother.&#xD;
&#xD;
               -  Non-viable fetus (missed abortion or blighted ovum) in the 1st trimester of&#xD;
                  pregnancy evidenced by criteria for diagnosis by TVS .&#xD;
&#xD;
               -  Previous C.S or Myomectomy (1 or more )&#xD;
&#xD;
               -  lack of any maternal diseases such as: heart disease, asthma, history of&#xD;
                  thromboembolism, cancer, renal failure, and liver diseases.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  * Medical problem in patient&#xD;
&#xD;
               -  Emergency conditions which need intervention .&#xD;
&#xD;
               -  History of allergy to misoprostol or letrozole drugs.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Ahmed Elsayed Aref</name>
      <address>
        <city>Sohag</city>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Ahmed Elsayed Aref</last_name>
      <phone>01097993202</phone>
      <email>draelsaied2018@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ahmed Elsayed Aref</name>
      <address>
        <city>Sohag</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 23, 2021</study_first_submitted>
  <study_first_submitted_qc>September 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Ahmed Elsayed Aref</investigator_full_name>
    <investigator_title>Ahmed Elsayed Aref</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cicatrix</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

